Review



mbm samples  (Darling Ingredients Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Darling Ingredients Inc mbm samples
    Mbm Samples, supplied by Darling Ingredients Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mbm+samples/pm25771530-37-0-11?v=Darling+Ingredients+Inc
    Average 90 stars, based on 1 article reviews
    mbm samples - by Bioz Stars, 2026-07
    90/100 stars

    Images



    Similar Products

    mbm patient samples  (Caris Life Sciences)
    90
    Caris Life Sciences mbm patient samples
    a IFNγ scores <t>for</t> <t>PCM</t> (blue, n = 350), <t>MBM</t> (orange, n = 94) and ECM (gray, n = 870). Black lines indicate median IFNγ score values. Kruskal–Wallis test with Benjamini-Hochberg correction; ****, corrected p < 0.0001; *, corrected p < 0.05. b PCM, MBM, and ECM were evaluated and classified by T cell-inflamed signature. The percentages of tumors with T cell-inflamed signatures (TIS(+); gray), undetermined (white), and lacking a T cell-inflamed signature (TIS(-); black). Chi-square test; **** p < 0.0001. c The percentage of PCM ( n = 276), MBM ( n = 72), and ECM ( n = 681) that are TMB-high and PD-L1(+). Chi-square test; ***, p < 0.0005. d Oncoplot including IFNγ scores (top, highest to lowest within PCM, blue; MBM, orange; ECM, gray), T cell-inflamed signature (green, T cell-inflamed tumors; gray, others), TMB (high, green; low, gray; white, data not available) and PD-L1 IHC staining (positive, green; negative, gray; white, data not available). e Percentage of tumors that are homozygous at HLA-I (HLA-A, HLA-B, and HLA-C) and HLA-II (HLA-DPA1, HLA-DPB1, HLA-DQB1, and HLA-DRB1) loci in PCM, MBM, and ECM. Chi-square test, not significant ( p > 0.05). f Assessment of neoantigen load with low (left), intermediate (middle), and high (right) HLA-binding affinity for PCM (blue), MBM (orange), and ECM (gray). Kruskal–Wallis test; not significant ( p > 0.05).
    Mbm Patient Samples, supplied by Caris Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mbm+samples/pmc10646102-160-13-26?v=Caris+Life+Sciences
    Average 90 stars, based on 1 article reviews
    mbm patient samples - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    molecular beam sampling system hpr-60 mbms  (Hiden Analytical)
    90
    Hiden Analytical molecular beam sampling system hpr-60 mbms
    a IFNγ scores <t>for</t> <t>PCM</t> (blue, n = 350), <t>MBM</t> (orange, n = 94) and ECM (gray, n = 870). Black lines indicate median IFNγ score values. Kruskal–Wallis test with Benjamini-Hochberg correction; ****, corrected p < 0.0001; *, corrected p < 0.05. b PCM, MBM, and ECM were evaluated and classified by T cell-inflamed signature. The percentages of tumors with T cell-inflamed signatures (TIS(+); gray), undetermined (white), and lacking a T cell-inflamed signature (TIS(-); black). Chi-square test; **** p < 0.0001. c The percentage of PCM ( n = 276), MBM ( n = 72), and ECM ( n = 681) that are TMB-high and PD-L1(+). Chi-square test; ***, p < 0.0005. d Oncoplot including IFNγ scores (top, highest to lowest within PCM, blue; MBM, orange; ECM, gray), T cell-inflamed signature (green, T cell-inflamed tumors; gray, others), TMB (high, green; low, gray; white, data not available) and PD-L1 IHC staining (positive, green; negative, gray; white, data not available). e Percentage of tumors that are homozygous at HLA-I (HLA-A, HLA-B, and HLA-C) and HLA-II (HLA-DPA1, HLA-DPB1, HLA-DQB1, and HLA-DRB1) loci in PCM, MBM, and ECM. Chi-square test, not significant ( p > 0.05). f Assessment of neoantigen load with low (left), intermediate (middle), and high (right) HLA-binding affinity for PCM (blue), MBM (orange), and ECM (gray). Kruskal–Wallis test; not significant ( p > 0.05).
    Molecular Beam Sampling System Hpr 60 Mbms, supplied by Hiden Analytical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mbm+samples/10__1002_slash_ppap__202000225-42-13-31?v=Hiden+Analytical
    Average 90 stars, based on 1 article reviews
    molecular beam sampling system hpr-60 mbms - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    molecular beam sampling mass spectrometry (mbms)  (Solid Phase Inc)
    90
    Solid Phase Inc molecular beam sampling mass spectrometry (mbms)
    a IFNγ scores <t>for</t> <t>PCM</t> (blue, n = 350), <t>MBM</t> (orange, n = 94) and ECM (gray, n = 870). Black lines indicate median IFNγ score values. Kruskal–Wallis test with Benjamini-Hochberg correction; ****, corrected p < 0.0001; *, corrected p < 0.05. b PCM, MBM, and ECM were evaluated and classified by T cell-inflamed signature. The percentages of tumors with T cell-inflamed signatures (TIS(+); gray), undetermined (white), and lacking a T cell-inflamed signature (TIS(-); black). Chi-square test; **** p < 0.0001. c The percentage of PCM ( n = 276), MBM ( n = 72), and ECM ( n = 681) that are TMB-high and PD-L1(+). Chi-square test; ***, p < 0.0005. d Oncoplot including IFNγ scores (top, highest to lowest within PCM, blue; MBM, orange; ECM, gray), T cell-inflamed signature (green, T cell-inflamed tumors; gray, others), TMB (high, green; low, gray; white, data not available) and PD-L1 IHC staining (positive, green; negative, gray; white, data not available). e Percentage of tumors that are homozygous at HLA-I (HLA-A, HLA-B, and HLA-C) and HLA-II (HLA-DPA1, HLA-DPB1, HLA-DQB1, and HLA-DRB1) loci in PCM, MBM, and ECM. Chi-square test, not significant ( p > 0.05). f Assessment of neoantigen load with low (left), intermediate (middle), and high (right) HLA-binding affinity for PCM (blue), MBM (orange), and ECM (gray). Kruskal–Wallis test; not significant ( p > 0.05).
    Molecular Beam Sampling Mass Spectrometry (Mbms), supplied by Solid Phase Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mbm+samples/10__1021_slash_acs__energyfuels__0c03561-65-55-30?v=Solid+Phase+Inc
    Average 90 stars, based on 1 article reviews
    molecular beam sampling mass spectrometry (mbms) - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    mbm samples  (Darling Ingredients Inc)
    90
    Darling Ingredients Inc mbm samples
    a IFNγ scores <t>for</t> <t>PCM</t> (blue, n = 350), <t>MBM</t> (orange, n = 94) and ECM (gray, n = 870). Black lines indicate median IFNγ score values. Kruskal–Wallis test with Benjamini-Hochberg correction; ****, corrected p < 0.0001; *, corrected p < 0.05. b PCM, MBM, and ECM were evaluated and classified by T cell-inflamed signature. The percentages of tumors with T cell-inflamed signatures (TIS(+); gray), undetermined (white), and lacking a T cell-inflamed signature (TIS(-); black). Chi-square test; **** p < 0.0001. c The percentage of PCM ( n = 276), MBM ( n = 72), and ECM ( n = 681) that are TMB-high and PD-L1(+). Chi-square test; ***, p < 0.0005. d Oncoplot including IFNγ scores (top, highest to lowest within PCM, blue; MBM, orange; ECM, gray), T cell-inflamed signature (green, T cell-inflamed tumors; gray, others), TMB (high, green; low, gray; white, data not available) and PD-L1 IHC staining (positive, green; negative, gray; white, data not available). e Percentage of tumors that are homozygous at HLA-I (HLA-A, HLA-B, and HLA-C) and HLA-II (HLA-DPA1, HLA-DPB1, HLA-DQB1, and HLA-DRB1) loci in PCM, MBM, and ECM. Chi-square test, not significant ( p > 0.05). f Assessment of neoantigen load with low (left), intermediate (middle), and high (right) HLA-binding affinity for PCM (blue), MBM (orange), and ECM (gray). Kruskal–Wallis test; not significant ( p > 0.05).
    Mbm Samples, supplied by Darling Ingredients Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mbm+samples/pm25771530-37-0-11?v=Darling+Ingredients+Inc
    Average 90 stars, based on 1 article reviews
    mbm samples - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    feedchektm mbm sample buffer  (Strategic Diagnostics Inc)
    90
    Strategic Diagnostics Inc feedchektm mbm sample buffer
    a IFNγ scores <t>for</t> <t>PCM</t> (blue, n = 350), <t>MBM</t> (orange, n = 94) and ECM (gray, n = 870). Black lines indicate median IFNγ score values. Kruskal–Wallis test with Benjamini-Hochberg correction; ****, corrected p < 0.0001; *, corrected p < 0.05. b PCM, MBM, and ECM were evaluated and classified by T cell-inflamed signature. The percentages of tumors with T cell-inflamed signatures (TIS(+); gray), undetermined (white), and lacking a T cell-inflamed signature (TIS(-); black). Chi-square test; **** p < 0.0001. c The percentage of PCM ( n = 276), MBM ( n = 72), and ECM ( n = 681) that are TMB-high and PD-L1(+). Chi-square test; ***, p < 0.0005. d Oncoplot including IFNγ scores (top, highest to lowest within PCM, blue; MBM, orange; ECM, gray), T cell-inflamed signature (green, T cell-inflamed tumors; gray, others), TMB (high, green; low, gray; white, data not available) and PD-L1 IHC staining (positive, green; negative, gray; white, data not available). e Percentage of tumors that are homozygous at HLA-I (HLA-A, HLA-B, and HLA-C) and HLA-II (HLA-DPA1, HLA-DPB1, HLA-DQB1, and HLA-DRB1) loci in PCM, MBM, and ECM. Chi-square test, not significant ( p > 0.05). f Assessment of neoantigen load with low (left), intermediate (middle), and high (right) HLA-binding affinity for PCM (blue), MBM (orange), and ECM (gray). Kruskal–Wallis test; not significant ( p > 0.05).
    Feedchektm Mbm Sample Buffer, supplied by Strategic Diagnostics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mbm+samples/10__1111_slash_j__1365___2621__2004__00858__x-117-0-9?v=Strategic+Diagnostics+Inc
    Average 90 stars, based on 1 article reviews
    feedchektm mbm sample buffer - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    mbm samples  (Rhone Poulenc Inc)
    90
    Rhone Poulenc Inc mbm samples
    a IFNγ scores <t>for</t> <t>PCM</t> (blue, n = 350), <t>MBM</t> (orange, n = 94) and ECM (gray, n = 870). Black lines indicate median IFNγ score values. Kruskal–Wallis test with Benjamini-Hochberg correction; ****, corrected p < 0.0001; *, corrected p < 0.05. b PCM, MBM, and ECM were evaluated and classified by T cell-inflamed signature. The percentages of tumors with T cell-inflamed signatures (TIS(+); gray), undetermined (white), and lacking a T cell-inflamed signature (TIS(-); black). Chi-square test; **** p < 0.0001. c The percentage of PCM ( n = 276), MBM ( n = 72), and ECM ( n = 681) that are TMB-high and PD-L1(+). Chi-square test; ***, p < 0.0005. d Oncoplot including IFNγ scores (top, highest to lowest within PCM, blue; MBM, orange; ECM, gray), T cell-inflamed signature (green, T cell-inflamed tumors; gray, others), TMB (high, green; low, gray; white, data not available) and PD-L1 IHC staining (positive, green; negative, gray; white, data not available). e Percentage of tumors that are homozygous at HLA-I (HLA-A, HLA-B, and HLA-C) and HLA-II (HLA-DPA1, HLA-DPB1, HLA-DQB1, and HLA-DRB1) loci in PCM, MBM, and ECM. Chi-square test, not significant ( p > 0.05). f Assessment of neoantigen load with low (left), intermediate (middle), and high (right) HLA-binding affinity for PCM (blue), MBM (orange), and ECM (gray). Kruskal–Wallis test; not significant ( p > 0.05).
    Mbm Samples, supplied by Rhone Poulenc Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mbm+samples/10__1071_slash_ar02055-16-14-23?v=Rhone+Poulenc+Inc
    Average 90 stars, based on 1 article reviews
    mbm samples - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    a IFNγ scores for PCM (blue, n = 350), MBM (orange, n = 94) and ECM (gray, n = 870). Black lines indicate median IFNγ score values. Kruskal–Wallis test with Benjamini-Hochberg correction; ****, corrected p < 0.0001; *, corrected p < 0.05. b PCM, MBM, and ECM were evaluated and classified by T cell-inflamed signature. The percentages of tumors with T cell-inflamed signatures (TIS(+); gray), undetermined (white), and lacking a T cell-inflamed signature (TIS(-); black). Chi-square test; **** p < 0.0001. c The percentage of PCM ( n = 276), MBM ( n = 72), and ECM ( n = 681) that are TMB-high and PD-L1(+). Chi-square test; ***, p < 0.0005. d Oncoplot including IFNγ scores (top, highest to lowest within PCM, blue; MBM, orange; ECM, gray), T cell-inflamed signature (green, T cell-inflamed tumors; gray, others), TMB (high, green; low, gray; white, data not available) and PD-L1 IHC staining (positive, green; negative, gray; white, data not available). e Percentage of tumors that are homozygous at HLA-I (HLA-A, HLA-B, and HLA-C) and HLA-II (HLA-DPA1, HLA-DPB1, HLA-DQB1, and HLA-DRB1) loci in PCM, MBM, and ECM. Chi-square test, not significant ( p > 0.05). f Assessment of neoantigen load with low (left), intermediate (middle), and high (right) HLA-binding affinity for PCM (blue), MBM (orange), and ECM (gray). Kruskal–Wallis test; not significant ( p > 0.05).

    Journal: NPJ Precision Oncology

    Article Title: Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases

    doi: 10.1038/s41698-023-00471-z

    Figure Lengend Snippet: a IFNγ scores for PCM (blue, n = 350), MBM (orange, n = 94) and ECM (gray, n = 870). Black lines indicate median IFNγ score values. Kruskal–Wallis test with Benjamini-Hochberg correction; ****, corrected p < 0.0001; *, corrected p < 0.05. b PCM, MBM, and ECM were evaluated and classified by T cell-inflamed signature. The percentages of tumors with T cell-inflamed signatures (TIS(+); gray), undetermined (white), and lacking a T cell-inflamed signature (TIS(-); black). Chi-square test; **** p < 0.0001. c The percentage of PCM ( n = 276), MBM ( n = 72), and ECM ( n = 681) that are TMB-high and PD-L1(+). Chi-square test; ***, p < 0.0005. d Oncoplot including IFNγ scores (top, highest to lowest within PCM, blue; MBM, orange; ECM, gray), T cell-inflamed signature (green, T cell-inflamed tumors; gray, others), TMB (high, green; low, gray; white, data not available) and PD-L1 IHC staining (positive, green; negative, gray; white, data not available). e Percentage of tumors that are homozygous at HLA-I (HLA-A, HLA-B, and HLA-C) and HLA-II (HLA-DPA1, HLA-DPB1, HLA-DQB1, and HLA-DRB1) loci in PCM, MBM, and ECM. Chi-square test, not significant ( p > 0.05). f Assessment of neoantigen load with low (left), intermediate (middle), and high (right) HLA-binding affinity for PCM (blue), MBM (orange), and ECM (gray). Kruskal–Wallis test; not significant ( p > 0.05).

    Article Snippet: A multi-institutional cohort of 1,314 patient samples, including PCM ( n = 350), MBM ( n = 94), and ECM ( n = 870) from the Caris Life Sciences database were analyzed in a CLIA/CAP-certified laboratory (Caris Life Sciences, Phoenix, AZ).

    Techniques: Immunohistochemistry, Binding Assay

    a Box plots showing computationally inferred immune cell abundance in PCM, MBM, and ECM using quanTIseq analysis. The data is displayed using the Tukey method for box and whiskers, with the center line indicating the median. Kruskal-Wallis test with Benjamini-Hochberg correction; *, corrected p < 0.05; **, corrected p < 0.005; ***, corrected p < 0.0005; ****, corrected p < 0.0001. b The mRNA levels of TNF , IL12A , and IL12B were compared between PCM, MBM, and ECM tumor samples. The data is displayed using the Tukey method for box and whiskers, with the center line indicating the median. Kruskal–Wallis test with Benjamini-Hochberg correction; **, corrected p < 0.005; ****, corrected p < 0.0001 c Heat map of Spearman rank correlation coefficients between TNF , IL12A , and IL12B mRNA and immune cell infiltrates calculated from bulk transcriptomic data in MBM. The numbers in each box show the correlation coefficient, where crossed boxes indicate non-significant correlation values ( p > 0.05). d Box plots of T cell exhaustion scores in PCM, MBM, and ECM. The data is displayed using the Tukey method for box and whiskers. Kruskal–Wallis test with Benjamini–Hochberg correction. e Percentage of PCM, MBM, and ECM with CD8 + T cells that have high dysfunction scores (composite z -score > 1.0) but low FGFBP2 mRNA levels (less than the median for the whole cohort). χ 2 test; **** p < 0.0001. f Oncoplot with T cell dysfunction score (top, highest to lowest within PCM, blue; MBM, orange; ECM, gray), FGFBP2 mRNA levels (middle), and CD8 + T cell abundance (bottom).

    Journal: NPJ Precision Oncology

    Article Title: Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases

    doi: 10.1038/s41698-023-00471-z

    Figure Lengend Snippet: a Box plots showing computationally inferred immune cell abundance in PCM, MBM, and ECM using quanTIseq analysis. The data is displayed using the Tukey method for box and whiskers, with the center line indicating the median. Kruskal-Wallis test with Benjamini-Hochberg correction; *, corrected p < 0.05; **, corrected p < 0.005; ***, corrected p < 0.0005; ****, corrected p < 0.0001. b The mRNA levels of TNF , IL12A , and IL12B were compared between PCM, MBM, and ECM tumor samples. The data is displayed using the Tukey method for box and whiskers, with the center line indicating the median. Kruskal–Wallis test with Benjamini-Hochberg correction; **, corrected p < 0.005; ****, corrected p < 0.0001 c Heat map of Spearman rank correlation coefficients between TNF , IL12A , and IL12B mRNA and immune cell infiltrates calculated from bulk transcriptomic data in MBM. The numbers in each box show the correlation coefficient, where crossed boxes indicate non-significant correlation values ( p > 0.05). d Box plots of T cell exhaustion scores in PCM, MBM, and ECM. The data is displayed using the Tukey method for box and whiskers. Kruskal–Wallis test with Benjamini–Hochberg correction. e Percentage of PCM, MBM, and ECM with CD8 + T cells that have high dysfunction scores (composite z -score > 1.0) but low FGFBP2 mRNA levels (less than the median for the whole cohort). χ 2 test; **** p < 0.0001. f Oncoplot with T cell dysfunction score (top, highest to lowest within PCM, blue; MBM, orange; ECM, gray), FGFBP2 mRNA levels (middle), and CD8 + T cell abundance (bottom).

    Article Snippet: A multi-institutional cohort of 1,314 patient samples, including PCM ( n = 350), MBM ( n = 94), and ECM ( n = 870) from the Caris Life Sciences database were analyzed in a CLIA/CAP-certified laboratory (Caris Life Sciences, Phoenix, AZ).

    Techniques:

    a The percentage of PCM (blue, n = 332), MBM (orange, n = 86), and ECM (gray, n = 801) with PTEN mutations. Chi-square test; ** p < 0.005. b ssGSEA analysis for normalized enrichment scores (NES) of hallmark angiogenesis pathway comparing tumors with PTEN mutations (green) and without PTEN mutations (gray) within PCM, MBM, and ECM groups. Black line indicates median. Mann-Whitney test; * p < 0.05. c The mRNA levels of key regulatory genes ( STAT3 , VEGFA , AKT1 , PIK3CA , and CCL2 ) in the angiogenesis pathway were cross compared between MBM tumors with PTEN mutations (green) and without PTEN mutations (gray). Black line indicates median. Mann-Whitney test; * p < 0.05.

    Journal: NPJ Precision Oncology

    Article Title: Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases

    doi: 10.1038/s41698-023-00471-z

    Figure Lengend Snippet: a The percentage of PCM (blue, n = 332), MBM (orange, n = 86), and ECM (gray, n = 801) with PTEN mutations. Chi-square test; ** p < 0.005. b ssGSEA analysis for normalized enrichment scores (NES) of hallmark angiogenesis pathway comparing tumors with PTEN mutations (green) and without PTEN mutations (gray) within PCM, MBM, and ECM groups. Black line indicates median. Mann-Whitney test; * p < 0.05. c The mRNA levels of key regulatory genes ( STAT3 , VEGFA , AKT1 , PIK3CA , and CCL2 ) in the angiogenesis pathway were cross compared between MBM tumors with PTEN mutations (green) and without PTEN mutations (gray). Black line indicates median. Mann-Whitney test; * p < 0.05.

    Article Snippet: A multi-institutional cohort of 1,314 patient samples, including PCM ( n = 350), MBM ( n = 94), and ECM ( n = 870) from the Caris Life Sciences database were analyzed in a CLIA/CAP-certified laboratory (Caris Life Sciences, Phoenix, AZ).

    Techniques: MANN-WHITNEY

    Ingenuity pathway analysis (IPA) shows a significant enrichment of pathways in MBM compared to ECM ( a ) and PCM ( b ). Orange node, enrichment in MBM; blue node, enrichment in ECM or PCM. c Differentially expressed genes (Log2FC; adjusted p < 0.01) in MBM compared to PCM. Only genes that were differentially expressed in MBM compared to both PCM and ECM are shown. Orange bars indicate genes that were upregulated in MBM and blue bars indicate genes that were downregulated in MBM.

    Journal: NPJ Precision Oncology

    Article Title: Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases

    doi: 10.1038/s41698-023-00471-z

    Figure Lengend Snippet: Ingenuity pathway analysis (IPA) shows a significant enrichment of pathways in MBM compared to ECM ( a ) and PCM ( b ). Orange node, enrichment in MBM; blue node, enrichment in ECM or PCM. c Differentially expressed genes (Log2FC; adjusted p < 0.01) in MBM compared to PCM. Only genes that were differentially expressed in MBM compared to both PCM and ECM are shown. Orange bars indicate genes that were upregulated in MBM and blue bars indicate genes that were downregulated in MBM.

    Article Snippet: A multi-institutional cohort of 1,314 patient samples, including PCM ( n = 350), MBM ( n = 94), and ECM ( n = 870) from the Caris Life Sciences database were analyzed in a CLIA/CAP-certified laboratory (Caris Life Sciences, Phoenix, AZ).

    Techniques:

    a GSEA analysis demonstrates a significant enrichment in of KEGG metabolic pathways in MBM versus PCM (left lane) or ECM (right lane). The normalized enrichment score (NES) is indicated by the size of the dot and the -log10 p value (cut off FDR < 0.05) is indicated by the color of the dot. b Heat maps of Spearman rank correlations between NES of OXPHOS, TCA cycle (TCA), and glycolysis (GLYC) determined from ssGSEA and computationally inferred immune cell abundance in PCM, MBM, and ECM. The numbers in each box show the correlation coefficient, where crossed boxes indicate non-significant correlation values ( p > 0.05).

    Journal: NPJ Precision Oncology

    Article Title: Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases

    doi: 10.1038/s41698-023-00471-z

    Figure Lengend Snippet: a GSEA analysis demonstrates a significant enrichment in of KEGG metabolic pathways in MBM versus PCM (left lane) or ECM (right lane). The normalized enrichment score (NES) is indicated by the size of the dot and the -log10 p value (cut off FDR < 0.05) is indicated by the color of the dot. b Heat maps of Spearman rank correlations between NES of OXPHOS, TCA cycle (TCA), and glycolysis (GLYC) determined from ssGSEA and computationally inferred immune cell abundance in PCM, MBM, and ECM. The numbers in each box show the correlation coefficient, where crossed boxes indicate non-significant correlation values ( p > 0.05).

    Article Snippet: A multi-institutional cohort of 1,314 patient samples, including PCM ( n = 350), MBM ( n = 94), and ECM ( n = 870) from the Caris Life Sciences database were analyzed in a CLIA/CAP-certified laboratory (Caris Life Sciences, Phoenix, AZ).

    Techniques: